A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Patients With Recurrent or Metastatic, Advanced Solid Tumors
Latest Information Update: 24 Oct 2024
At a glance
- Drugs IMB 071703 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Beijing Immunoah Pharma Tech
Most Recent Events
- 04 Jun 2024 Results (n=7) assessing initial data from a phase Ia study were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 12 Mar 2024 New trial record